NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

JNJ

Johnson & Johnson

Jul 14 • 04:00PM ET

156.82

Dollar change -0.08
Percentage change -0.05	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: MRK PFE NVS AMGN BMY LLY GSK ABT MDT SYK

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM DGRO QUAL

Scroll to Statements

Index	DJIA, S&P 500	P/E	17.43	EPS (ttm)	9.00	Insider Own	0.14%	Shs Outstand	2.41B	Perf Week	1.00%
Market Cap	377.32B	Forward P/E	14.07	EPS next Y	11.14	Insider Trans	-0.60%	Shs Float	2.40B	Perf Month	1.00%
Enterprise Value	390.79B	PEG	2.90	EPS next Q	2.68	Inst Own	73.56%	Short Float	0.66%	Perf Quarter	5.47%
Income	21.81B	P/S	4.22	EPS this Y	6.58%	Inst Trans	1.15%	Short Ratio	1.98	Perf Half Y	10.23%
Sales	89.33B	P/B	4.83	EPS next Y	4.75%	ROA	11.93%	Short Interest	15.82M	Perf YTD	8.44%
Book/sh	32.47	P/C	9.73	EPS next 5Y	6.01%	ROE	29.45%	52W High	169.99 -7.75%	Perf Year	4.95%
Cash/sh	16.12	P/FCF	18.52	EPS past 3/5Y	-9.49% 0.55%	ROIC	18.73%	52W Low	140.68 11.47%	Perf 3Y	-12.15%
Dividend Est.	5.15 (3.29%)	EV/EBITDA	13.67	Sales past 3/5Y	-1.79% 1.58%	Gross Margin	68.24%	Volatility	1.49% 1.39%	Perf 5Y	9.78%
Dividend TTM	5.02 (3.20%)	EV/Sales	4.37	EPS Y/Y TTM	29.21%	Oper. Margin	23.83%	ATR (14)	2.24	Perf 10Y	59.69%
Dividend Ex-Date	May 27, 2025	Quick Ratio	1.03	Sales Y/Y TTM	-0.37%	Profit Margin	24.41%	RSI (14)	58.48	Recom	2.20
Dividend Gr. 3/5Y	5.43% 5.54%	Current Ratio	1.26	EPS Q/Q	238.80%	SMA20	1.69%	Beta	0.39	Target Price	170.79
Payout	84.80%	Debt/Eq	0.67	Sales Q/Q	2.39%	SMA50	1.88%	Rel Volume	1.27	Prev Close	156.90
Employees	138100	LT Debt/Eq	0.49	Earnings	Jul 16 BMO	SMA200	1.01%	Avg Volume	7.99M	Price	156.82
IPO	Sep 25, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.33% 1.55%	Trades		Volume	10,183,913	Change	-0.05%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$153
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175
Oct-14-22	Reiterated	BofA Securities	Neutral	$185 → $178
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform	$200
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$173
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform	$180 → $183

Show Previous Ratings

Today 05:09PM	These 3 Undervalued Stocks Could Surge as Value Rotation Nears (MarketBeat)
04:58PM	Earnings live: Second quarter earnings season set to kick off with big banks leading the way (Yahoo Finance)
04:45PM	Earnings to Watch This Week (The Wall Street Journal)
04:24PM	Kenvue Yo-Yoes After Tylenol-Maker Unveils New CEO, Strategic Review (Investor's Business Daily)
07:22AM	Kenvue Seeks Its Own Band-Aid With CEO Departure and Strategic Review. The Stock Rises. (Barrons.com)
11:50AM	Loading…
11:50AM	Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors (Fortune)
11:03AM	Pre-Markets in the Red to Start a Fresh Week (Zacks)
10:24AM	Kenvue Reverses Premarket Gains After Tylenol-Maker Unveils New CEO, Strategic Review (Investor's Business Daily)
10:08AM	Big Week of Inflation Data, Q2 Earnings Reports (Zacks)
09:34AM	Zimmer to acquire Monogram Technologies for $177 million, boosting robotics portfolio (Reuters)
09:32AM	Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure (Zacks)
09:17AM	Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings? (Zacks)
08:20AM	Kenvue CEO Departs As Company Launches Strategic Review (The Wall Street Journal)
07:56AM	Kenvue CEO Mongon leaves the consumer health company as it continues its strategic review (Associated Press Finance)
07:00AM	Option Volatility And Earnings Report For July 14 - 18 (Barchart)
06:57AM	Loading…
06:57AM	Tylenol maker Kenvue's CEO quits amid board's strategic review (Reuters)
04:17AM	Prostate Care Market Report 2025-2031 \| Medtronic, Johnson & Johnson, Boston Scientific, and Abbott Laboratories Dominate through Product Innovations, Clinical Trials, M&As, and Strategic Partnerships (GlobeNewswire)
Jul-13-25 05:00PM	China Biotechs Stunning Advance Is Changing the Worlds Drug Pipeline (Bloomberg)
03:19PM	Stock Market Week Ahead: Blue Chips, Big Banks, GE Aerospace And Netflix Launch Q2, Congress Mulls Cryptos (Investor's Business Daily)
02:00PM	Wells Fargo, Citi, Netflix, J&J, and More Stocks to Watch This Week (Barrons.com)
10:00AM	Earnings this week will be the first test of markets' newfound trade-war nonchalance (MarketWatch)
07:51AM	Inflation data, big bank earnings, and Netflix results: What to watch this week (Yahoo Finance)
05:12AM	This Stock Has Increased 4,720%: Here's Why It's Still a Buy (Motley Fool)
05:00AM	What To Expect in Markets This Week: Big Bank Earnings, June Inflation, Retail Sales Data (Investopedia)
Jul-12-25 02:32PM	Johnson & Johnson (JNJ): I Would "Love" If Trump Praised The Company, Says Jim Cramer (Insider Monkey)
09:36AM	FDA willing to trade faster drug reviews for lower prices, Bloomberg reports (TipRanks)
Jul-11-25 06:00PM	Business Lookahead: US inflation reading, China's GDP figures (Reuters Videos)
04:56PM	Big pharma's multiple looming patent cliffs: What to know (Yahoo Finance Video)
11:10AM	Pre-Markets Red on Trump's Tariff Threats to Canada (Zacks)
10:34AM	New Tariff Talk Sends Pre-Markets Off Record Highs (Zacks)
10:10AM	Loading…
10:10AM	Bayer Wins Hormone-Free Treatment Approval for Women in the UK (Zacks)
09:15AM	Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics (Zacks)
08:31AM	TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock? (Zacks)
08:00AM	3 AI-Driven Medical Device Stocks to Watch in 2025 (Zacks)
07:48AM	Johnson & Johnson (JNJ) Declined Amid Broad Sell-Off in Healthcare (Insider Monkey)
04:05AM	Ulcerative Colitis Drug Market Analysis and Forecast, 2025-2035 \| Anti-TNF a Agents and Interleukin Antagonists Spearhead Therapeutic Developments (GlobeNewswire)
04:01AM	Psoriatic Arthritis Market Report 2025-2035 \| Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma (GlobeNewswire)
03:55AM	What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill (Motley Fool)
03:10AM	2 Dividend Stocks to Double Up on Right Now (Motley Fool)
Jul-10-25 11:40AM	Johnson & Johnson Submits Schizophrenia Drug CAPLYTA sNDA to FDA Based on Positive Relapse Prevention Data (Insider Monkey)
09:34AM	Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump (Zacks)
08:25AM	Hologic's GYN Surgical Dominance: What's Powering the Road Ahead? (Zacks)
Jul-09-25 01:45PM	Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade (Reuters)
11:41AM	Wall Street waves off Trump's 200% pharma tariff threat (Yahoo Finance)
10:00AM	Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:40AM	Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term (Zacks)
09:24AM	Merck Faces Multiple Challenges: Will It Steer Through Successfully? (Zacks)
09:11AM	JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now? (Zacks)
08:40AM	SpaceX Just Made Elon Musk $20 Billion Richer (Barrons.com)
08:18AM	Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks (Zacks)
01:03AM	Johnson & Johnson (JNJ) Applied to the European Medicines Agency to Expand AKEEGA Usage (Insider Monkey)
Jul-08-25 08:27AM	How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results? (Zacks)
08:00AM	Supplemental new drug application submitted to U.S. FDA for CAPLYTA (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo (PR Newswire)
06:03AM	Analysis: 'Trump Effect' website takes credit for US investment made under Biden (Reuters)
Jul-07-25 09:50AM	Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock (Zacks)
09:30AM	Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales? (Zacks)
06:36AM	J&Js Abiomed recalls heart pump controllers after 3 patients die (MedTech Dive)
06:07AM	Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Dividend Stock Instead? (Motley Fool)
Jul-06-25 03:35AM	J.P. Morgan Maintained Their Hold Rating on Johnson & Johnson (JNJ) (Insider Monkey)
Jul-04-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
04:19AM	North America Beta-Glucan Market Forecast and Company Analysis Report 2025-2033 Featuring Koninklijke Philips, EDAP TMS, Johnson & Johnson, Medtronic, Hitachi, Theraclion, Stryker, and GE (GlobeNewswire)
03:22AM	Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds (Insider Monkey)
Jul-03-25 12:10PM	Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again (Zacks)
11:45AM	Johnson & Johnson (JNJ) Could Be a Great Choice (Zacks)
09:03AM	The Zacks Analyst Blog Highlights Johnson & Johnson, The Home Depot, Micron Technology, Autoscope Technologies and Nova LifeStyle (Zacks)
09:00AM	Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now? (Zacks)
08:41AM	Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations (GlobeNewswire)
08:30AM	MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE (Zacks)
07:44AM	Regeneron nabs dosing edge with Lynozyfics FDA approval in multiple myeloma (Pharmaceutical Technology)
Jul-02-25 04:30PM	Top Analyst Reports for Johnson & Johnson, Home Depot and Micron (Zacks)
09:07AM	Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth? (Zacks)
Jul-01-25 05:45PM	Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts (Zacks)
03:06PM	A Promising Depression Drug Works. Psychedelics Are Back. (Barrons.com)
06:20AM	Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? (Zacks)
06:20AM	Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)? (Zacks)
06:20AM	Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar? (Zacks)
Jun-30-25 02:33PM	Wall Street Backs Los Angeles Wildfire Lawsuits, Chasing Billions (Bloomberg)
01:27PM	PJM Appoints Deena O'Brien as Senior Director of Communications (PR Newswire)
10:00AM	The Hackett Group® Announces Winners of the 2025 Hackett Innovation Awards (Business Wire)
07:00AM	Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy (PR Newswire)
06:45AM	Vicarious Surgical Announces Election of New Directors (Business Wire)
Jun-27-25 05:38AM	Here's What to Expect From Johnson & Johnson's Next Earnings Report (Barchart)
04:12AM	Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It. (Motley Fool)
01:16AM	How PepsiCo, Johnson & Johnson, And Skyworks Solutions Can Put Cash In Your Pocket (Benzinga)
Jun-26-25 09:03PM	Why JNJ Is a Long-Term Winner (Insider Monkey)
09:40AM	J&J's MedTech Segment Slowing Down: Will its Sales Recover in 2025? (Zacks)
08:45AM	Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever (Motley Fool)
06:12AM	Retinitis Pigmentosa Research Report 2025: $25+ Bn Market Opportunities and Strategies to 2034 - Gene Therapy Poised as Fastest Growing Treatment Segment, Strategic Collaborations Drive Advancements (GlobeNewswire)
06:00AM	J&J teams with Nvidia, Amazon on fund for AI surgery solutions (MedTech Dive)
Jun-25-25 03:08PM	Johnson & Johnson CAR T Therapy Shows 80% Response in Lymphoma Trial (Insider Monkey)
04:29AM	Johnson & Johnson (JNJ) Launches Two New Plating Systems in the US (Insider Monkey)
03:47AM	Johnson & Johnson MedTech Expands VOLT Platform With New Wrist, Upper Arm Fracture Systems (Insider Monkey)
Jun-24-25 01:06PM	Johnson & Johnson announces new data presented at EAN of IMAAVY (TipRanks)
12:20PM	MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal (Zacks)
10:25AM	Pfizer to Face Several Headwinds: Can It Successfully Navigate Them? (Zacks)
08:00AM	5 Dividend Stocks Poised to Profit From the AI Efficiency Boom (Motley Fool)
05:18AM	J&J introduces disposable contact lens for astigmatism and presbyopia (Medical Device Network)
03:39AM	How a Big Pharma veteran looks to stand out in biotech as a unique drug hunter (Pharma Voice)
Jun-23-25 02:31PM	Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing (Benzinga)
09:51AM	Compasss Psychedelic Drug to Treat Depression Meets Goal in Trial (Bloomberg)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '25	Option Exercise	0.00	25,255	0	40,797	May 05 05:10 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Option Exercise	101.87	6,999	712,988	28,000	Feb 26 06:42 PM
Decker Robert J	VP Corporate Controller	Feb 25 '25	Sale	165.88	6,999	1,160,994	21,001	Feb 26 06:42 PM
Decker Robert J	Officer	Feb 25 '25	Proposed Sale	165.88	6,999	1,161,010		Feb 25 03:05 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	2,806	0	17,904	Feb 18 09:46 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '25	Option Exercise	0.00	1,029	0	15,501	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 14 '25	Option Exercise	0.00	1,765	0	15,111	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '25	Option Exercise	0.00	499	0	13,539	Feb 18 09:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '25	Sale	156.15	403	62,928	15,098	Feb 18 09:33 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '25	Option Exercise	0.00	607	0	91,037	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 14 '25	Option Exercise	0.00	7,367	0	96,674	Feb 18 09:16 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '25	Option Exercise	0.00	651	0	89,603	Feb 18 09:16 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '25	Option Exercise	0.00	1,971	0	6,113	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 14 '25	Option Exercise	0.00	19,330	0	20,661	Feb 18 09:13 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '25	Option Exercise	0.00	1,779	0	1,779	Feb 18 09:13 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '25	Option Exercise	0.00	1,350	0	15,927	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '25	Option Exercise	0.00	1,594	0	171,110	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 14 '25	Option Exercise	0.00	19,518	0	185,924	Feb 18 09:08 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '25	Option Exercise	0.00	1,302	0	167,221	Feb 18 09:08 PM
Swanson James D.	EVP, CIO	Feb 15 '25	Option Exercise	0.00	492	0	16,762	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 14 '25	Option Exercise	0.00	5,079	0	19,739	Feb 18 09:06 PM
Swanson James D.	EVP, CIO	Feb 13 '25	Option Exercise	0.00	447	0	15,019	Feb 18 09:06 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '25	Option Exercise	0.00	419	0	13,095	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 14 '25	Option Exercise	0.00	2,608	0	14,576	Feb 18 09:05 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '25	Option Exercise	0.00	411	0	12,100	Feb 18 09:05 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 15 '25	Option Exercise	0.00	961	0	10,321	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 14 '25	Option Exercise	0.00	2,203	0	11,366	Feb 18 09:03 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '25	Option Exercise	0.00	651	0	8,991	Feb 18 09:03 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '25	Option Exercise	0.00	3,682	0	397,525	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 14 '25	Option Exercise	0.00	24,335	0	415,205	Feb 18 09:02 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '25	Option Exercise	0.00	3,470	0	392,498	Feb 18 09:02 PM
Decker Robert J	VP Corporate Controller	Feb 15 '25	Option Exercise	0.00	339	0	20,116	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 14 '25	Option Exercise	0.00	2,201	0	21,373	Feb 18 09:01 PM
Decker Robert J	VP Corporate Controller	Feb 13 '25	Option Exercise	0.00	312	0	19,285	Feb 18 09:01 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '25	Option Exercise	0.00	492	0	21,839	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 14 '25	Option Exercise	0.00	4,740	0	24,591	Feb 18 08:58 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '25	Option Exercise	0.00	408	0	20,242	Feb 18 08:58 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 07 '25	Option Exercise	100.06	126,369	12,644,482	489,671	Feb 11 07:43 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 07 '25	Option Exercise	100.06	32,762	3,278,166	115,028	Feb 11 07:42 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 07 '25	Option Exercise	100.06	58,504	5,853,910	213,355	Feb 11 07:41 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Option Exercise	100.06	13,015	1,302,281	13,015	Feb 11 07:40 PM
Wolk Joseph J	Exec VP, CFO	Feb 07 '25	Sale	153.89	13,015	2,002,878	0	Feb 11 07:40 PM
Wolk Joseph J	Officer	Feb 07 '25	Proposed Sale	153.89	13,015	2,002,924		Feb 07 01:27 PM
WEINBERGER MARK A	Director	Dec 12 '24	Buy	147.22	1,000	147,220	1,000	Dec 12 05:27 PM
Hait William	Former Officer	Dec 04 '24	Proposed Sale	149.90	25,742	3,858,598		Dec 04 01:25 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Option Exercise	100.06	5,635	563,838	24,608	Sep 03 04:48 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Sale	165.06	5,635	930,113	18,973	Sep 03 04:48 PM
Decker Robert J	Officer	Aug 30 '24	Proposed Sale	165.06	5,635	930,113		Aug 30 03:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience